O’Melveny represented Pharmaron Beijing Co., Ltd. (300759.SZ and 3759.HK), in its approximately HK$4.6 billion (approximately US$588 million) dual primary listing and H share offering in Hong…
This content is for Standard 1 Year members only. LoginJoin Now
Author: Michael Patrini
…
This content is for Standard 1 Year members only. LoginJoin Now